Literature DB >> 16056097

Acidic oligosaccharides from pectin hydrolysate as new component for infant formulae: effect on intestinal flora, stool characteristics, and pH.

S Fanaro1, J Jelinek, B Stahl, G Boehm, R Kock, V Vigi.   

Abstract

OBJECTIVES: To come even closer to the functional composition of human milk, acidic oligosaccharides (AOS) from pectin were added to well known neutral prebiotics (galacto-oligosaccharides (GOS) and long-chain fructo-oligosaccharides (FOS)). The effect of AOS and GOS/FOS/AOS on intestinal flora, stool characteristics as well as acceptance and tolerance was investigated.
METHODS: Human milk contains 75% to 85% neutral and 15% to 25% acidic oligosaccharides. In this prospective, randomized, double blind study, a mixture of 80% neutral oligosaccharides (from long-chain galacto- and long-chain fructo-oligosaccharides) with 20% acidic oligosaccharides derived from pectin hydrolysis was investigated. Forty-six term infants were fed a standard formula supplemented with either maltodextrin as control (n=15), or with 0.2 g acidic oligosaccharides (n=16), or with the latter plus 0.6 g neutral oligosaccharides (mixture of galacto- and fructo-oligosaccharides; n=15). Fecal flora using plating technique and pH were measured. Stool characteristics and possible side effects (crying, vomiting, and regurgitation) were recorded.
RESULTS: There was no difference in the bifidobacteria counts between the control and the group supplemented with acidic oligosaccharides alone (8.75+/-0.50 vs. 8.58+/-0.94 log colony forming units [CFU]/g stool). In infants fed the combination of acidic and neutral oligosaccharides, bifidobacteria were increased (9.61+/-0.70 log CFU/g stool; P<0.01). The same pattern was observed with lactobacilli. Stool consistency was softest in infants fed the complete oligosaccharide mixture, but also in those fed formula supplemented with acidic oligosaccharides alone, the stool consistency was significantly softer compared with the control group. Fecal pH increased in the controls, remained constant in acidic oligosaccharides alone, and decreased in the complete mixture of oligosaccharides group.
CONCLUSION: There was no difference in growth, crying, vomiting, and regurgitation patterns between the groups. In summary, acidic oligosaccharides from pectin hydrolysate are well tolerated as ingredient in infant formulae but do not affect intestinal microecology.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16056097     DOI: 10.1097/01.mpg.0000172747.64103.d7

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  14 in total

1.  The effect of enteral supplementation of specific neutral and acidic oligosaccharides on the faecal microbiota and intestinal microenvironment in preterm infants.

Authors:  E A M Westerbeek; R A Slump; H N Lafeber; J Knol; G Georgi; W P F Fetter; R M van Elburg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-09-09       Impact factor: 3.267

Review 2.  The role of early life nutrition in the establishment of gastrointestinal microbial composition and function.

Authors:  Erin C Davis; Mei Wang; Sharon M Donovan
Journal:  Gut Microbes       Date:  2017-01-09

3.  Characterization of partial acid hydrolysates of citrus pectin for their pasting, rheological and thermal properties.

Authors:  Nidhi Dangi; Baljeet S Yadav
Journal:  J Food Sci Technol       Date:  2020-02-25       Impact factor: 2.701

4.  A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids.

Authors:  Mark A Underwood; Nita H Salzman; Stephen H Bennett; Melissa Barman; David A Mills; Angela Marcobal; Daniel J Tancredi; Charles L Bevins; Michael P Sherman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-02       Impact factor: 2.839

5.  Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin.

Authors:  Cheppail Ramachandran; Barry J Wilk; Arland Hotchkiss; Hoa Chau; Isaac Eliaz; Steven J Melnick
Journal:  BMC Complement Altern Med       Date:  2011-08-04       Impact factor: 3.659

6.  Tolerance and safety evaluation in a large cohort of healthy infants fed an innovative prebiotic formula: a randomized controlled trial.

Authors:  Pasqua Piemontese; Maria L Giannì; Christian P Braegger; Gaetano Chirico; Christoph Grüber; Josef Riedler; Sertac Arslanoglu; Margriet van Stuijvenberg; Günther Boehm; Jürgen Jelinek; Paola Roggero
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

7.  Stool fatty acid soaps, stool consistency and gastrointestinal tolerance in term infants fed infant formulas containing high sn-2 palmitate with or without oligofructose: a double-blind, randomized clinical trial.

Authors:  Joyce Nowacki; Hung-Chang Lee; Reyin Lien; Shao-Wen Cheng; Sung-Tse Li; Manjiang Yao; Robert Northington; Ingrid Jan; Gisella Mutungi
Journal:  Nutr J       Date:  2014-11-05       Impact factor: 3.271

Review 8.  Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review.

Authors:  Mary N Mugambi; Alfred Musekiwa; Martani Lombard; Taryn Young; Reneé Blaauw
Journal:  Nutr J       Date:  2012-10-04       Impact factor: 3.271

9.  Design of a randomised controlled trial on immune effects of acidic and neutral oligosaccharides in the nutrition of preterm infants: carrot study.

Authors:  Elisabeth A M Westerbeek; Ruurd M van Elburg; Anemone van den Berg; Jolice van den Berg; Jos W R Twisk; Willem P F Fetter; Harrie N Lafeber
Journal:  BMC Pediatr       Date:  2008-10-23       Impact factor: 2.125

Review 10.  Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: a systematic review.

Authors:  Mary N Mugambi; Alfred Musekiwa; Martani Lombard; Taryn Young; Reneé Blaauw
Journal:  BMC Med Res Methodol       Date:  2013-11-13       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.